An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection
Kevin P. Egan(University of Pennsylvania), Harvey M. Friedman(University of Pennsylvania), Sita Awasthi(University of Pennsylvania), Norbert Pardi(University of Pennsylvania), Drew Weissman(California University of Pennsylvania), Gary H. Cohen(University of Pennsylvania), Alexis M. Naughton(University of Pennsylvania), Lauren M. Hook(University of Pennsylvania)
Cited by 65
Related Papers
mRNA vaccines — a new era in vaccinology
|Nature Reviews Drug Discovery|2018|4.4k
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
|Immunity|2021|713
An ionizable lipid toolbox for RNA delivery
|Nature Communications|2021|581
Nanomaterial Delivery Systems for mRNA Vaccines
|Vaccines|2021|546